HRP990246A2
(en)
|
1998-08-07 |
2000-06-30 |
Du Pont Pharm Co |
Succinoylamino benzodiazepines as inhibitors of a beta protein production
|
WO2000038618A2
(en)
|
1998-12-24 |
2000-07-06 |
Du Pont Pharmaceuticals Company |
SUCCINOYLAMINO BENZODIAZEPINES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
|
US6960576B2
(en)
|
1999-09-13 |
2005-11-01 |
Bristol-Myers Squibb Pharma Company |
Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
|
US6503902B2
(en)
|
1999-09-13 |
2003-01-07 |
Bristol-Myers Squibb Pharma Company |
Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
|
EP1222176A1
(en)
|
1999-10-08 |
2002-07-17 |
Bristol-Myers Squibb Pharma Company |
AMINO LACTAM SULFONAMIDES AS INHIBITORS OF A$g(b) PROTEIN PRODUCTION
|
US7049324B1
(en)
|
1999-11-15 |
2006-05-23 |
Ashis Kumar Saha |
Triazoles as farnesyl transferase inhibitors
|
ES2304996T3
(es)
*
|
1999-11-15 |
2008-11-01 |
Janssen Pharmaceutica Nv |
Triazoles como inhibidores de farnesil transferasa.
|
AU2001239791A1
(en)
|
2000-02-17 |
2001-08-27 |
Du Pont Pharmaceuticals Company |
Succinoylamino carbocycles and heterocycles as inhibitors of abeta protein production
|
CN1434803A
(zh)
|
2000-04-03 |
2003-08-06 |
布里斯托尔-迈尔斯斯奎布药品公司 |
作为Aβ蛋白质产生抑制剂的环内酰胺
|
MXPA02009755A
(es)
|
2000-04-03 |
2003-03-27 |
Bristol Myers Squibb Pharma Co |
Lactamas ciclicas como inhibidores de la produccion de proteina a-beta.
|
CA2404273A1
(en)
|
2000-04-11 |
2001-10-18 |
Bristol-Myers Squibb Pharma Company |
Substituted lactams as inhibitors of a.beta. protein production
|
AU783857B2
(en)
|
2000-06-01 |
2005-12-15 |
Bristol-Myers Squibb Pharma Company |
Lactams substituted by cyclic succinates as inhibitors of a beta protein production
|
US20030216257A1
(en)
*
|
2000-07-18 |
2003-11-20 |
Ingo Sagasser |
1-aryl-4-alkyl halide-2(1h)-pyridones and their use as herbicides
|
DE60335635D1
(de)
|
2002-05-22 |
2011-02-17 |
Amgen Inc |
Aminopyrimidin-derivate zur verwendung als vanilloid-rezeptor-liganden zur behandlung von schmerzen
|
MXPA05001456A
(es)
|
2002-08-08 |
2005-06-06 |
Amgen Inc |
Ligandos del receptor vanilloide y su uso en tratamientos.
|
MY139645A
(en)
|
2004-02-11 |
2009-10-30 |
Amgen Inc |
Vanilloid receptor ligands and their use in treatments
|
US7534798B2
(en)
|
2004-02-11 |
2009-05-19 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
AP2007004047A0
(en)
|
2005-01-20 |
2007-06-30 |
Pfizer Ltd |
Substituted triazole derivatives as oxtocin antagonists
|
WO2006089311A1
(en)
|
2005-02-15 |
2006-08-24 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
WO2006123182A2
(en)
|
2005-05-17 |
2006-11-23 |
Merck Sharp & Dohme Limited |
Cyclohexyl sulphones for treatment of cancer
|
KR101331768B1
(ko)
|
2005-11-08 |
2013-11-22 |
버텍스 파마슈티칼스 인코포레이티드 |
Atp 결합 카세트 수송체의 헤테로사이클릭 조정제
|
US7671221B2
(en)
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
EP2083831B1
(en)
|
2006-09-22 |
2013-12-25 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
US7754739B2
(en)
|
2007-05-09 |
2010-07-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
EP2336120B1
(en)
|
2007-01-10 |
2014-07-16 |
MSD Italia S.r.l. |
Combinations containing amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
JP5330274B2
(ja)
|
2007-03-01 |
2013-10-30 |
ノバルティス アーゲー |
Pimキナーゼ阻害剤およびその使用方法
|
WO2008141119A2
(en)
|
2007-05-09 |
2008-11-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of cftr
|
AU2008254425A1
(en)
|
2007-05-21 |
2008-11-27 |
Novartis Ag |
CSF-1R inhibitors, compositions, and methods of use
|
US8389553B2
(en)
|
2007-06-27 |
2013-03-05 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino derivatives as histone deacetylase inhibitors
|
KR20150066608A
(ko)
|
2007-12-07 |
2015-06-16 |
버텍스 파마슈티칼스 인코포레이티드 |
사이클로알킬카복시아미도-피리딘 벤조산의 제조 방법
|
SG186638A1
(en)
|
2007-12-07 |
2013-01-30 |
Vertex Pharma |
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
|
CA2716109C
(en)
|
2008-02-28 |
2016-07-19 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl derivatives as cftr modulators
|
US8691825B2
(en)
|
2009-04-01 |
2014-04-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of AKT activity
|
US8765747B2
(en)
|
2009-06-12 |
2014-07-01 |
Dana-Farber Cancer Institute, Inc. |
Fused 2-aminothiazole compounds
|
KR101485645B1
(ko)
|
2009-10-14 |
2015-01-22 |
머크 샤프 앤드 돔 코포레이션 |
p53 활성을 증가시키는 치환된 피페리딘 및 그의 용도
|
US9180127B2
(en)
|
2009-12-29 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
KR20130006664A
(ko)
|
2010-03-16 |
2013-01-17 |
다나-파버 캔서 인스티튜트 인크. |
인다졸 화합물 및 그의 용도
|
RU2592368C2
(ru)
|
2010-04-07 |
2016-07-20 |
Вертекс Фармасьютикалз Инкорпорейтед |
ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, ВКЛЮЧАЮЩИЕ 3-(2, 2-ДИФТОРБЕНЗО[d][1, 3]ДИОКСОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДО)-3-МЕТИЛПИРИДИН-2-ИЛ)БЕНЗОЙНУЮ КИСЛОТУ, И ИХ ВВЕДЕНИЕ
|
US8999957B2
(en)
|
2010-06-24 |
2015-04-07 |
Merck Sharp & Dohme Corp. |
Heterocyclic compounds as ERK inhibitors
|
CN107090456B
(zh)
|
2010-08-02 |
2022-01-18 |
瑟纳治疗公司 |
使用短干扰核酸的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1基因表达的抑制
|
EP4079856A1
(en)
|
2010-08-17 |
2022-10-26 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
|
EP2608669B1
(en)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
EP2615916B1
(en)
|
2010-09-16 |
2017-01-04 |
Merck Sharp & Dohme Corp. |
Fused pyrazole derivatives as novel erk inhibitors
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
EP2654748B1
(en)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazole derivatives useful as erk inhibitors
|
US20140045847A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
|
EP2770987B1
(en)
|
2011-10-27 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
WO2013074986A1
(en)
|
2011-11-17 |
2013-05-23 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-jun-n-terminal kinase (jnk)
|
EP2844261B1
(en)
|
2012-05-02 |
2018-10-17 |
Sirna Therapeutics, Inc. |
SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
|
EP2900241B1
(en)
|
2012-09-28 |
2018-08-08 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP2909194A1
(en)
|
2012-10-18 |
2015-08-26 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
US9758522B2
(en)
|
2012-10-19 |
2017-09-12 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
WO2014063054A1
(en)
|
2012-10-19 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
|
SI2925888T1
(en)
|
2012-11-28 |
2018-02-28 |
Merck Sharp & Dohme Corp. |
Compounds and methods for the treatment of cancer
|
RU2690663C2
(ru)
|
2012-12-20 |
2019-06-05 |
Мерк Шарп И Доум Корп. |
Замещенные имидазопиридины в качестве ингибиторов hdm2
|
US9540377B2
(en)
|
2013-01-30 |
2017-01-10 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as HDM2 inhibitors
|
EP3041938A1
(en)
|
2013-09-03 |
2016-07-13 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
AU2014337044A1
(en)
|
2013-10-18 |
2016-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
CA2927917C
(en)
|
2013-10-18 |
2022-08-09 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of proliferative diseases
|
AU2014349010C1
(en)
|
2013-11-12 |
2020-08-06 |
Vertex Pharmaceuticals Incorporated |
Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
WO2015164604A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
SG10201900631TA
(en)
|
2014-08-01 |
2019-02-27 |
Nuevolution As |
Compounds active towards bromodomains
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
JP6494757B2
(ja)
|
2014-11-18 |
2019-04-03 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
ハイスループット試験高速液体クロマトグラフィーを行うプロセス
|
CA2972239A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
EP3273966B1
(en)
|
2015-03-27 |
2023-05-03 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
AU2016276963C1
(en)
|
2015-06-12 |
2021-08-05 |
Dana-Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
WO2017044858A2
(en)
|
2015-09-09 |
2017-03-16 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
CN118267470A
(zh)
|
2017-04-13 |
2024-07-02 |
赛罗帕私人有限公司 |
抗SIRPα抗体
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
US11981701B2
(en)
|
2018-08-07 |
2024-05-14 |
Merck Sharp & Dohme Llc |
PRMT5 inhibitors
|
EP3833668A4
(en)
|
2018-08-07 |
2022-05-11 |
Merck Sharp & Dohme Corp. |
PRMT5 INHIBITORS
|
CN111848521A
(zh)
*
|
2020-08-26 |
2020-10-30 |
韶远科技(上海)有限公司 |
一种2-取代-4-烷氧基咪唑化合物的制备方法
|